This Senate resolution declares that over 25 years of real-world evidence and hundreds of peer-reviewed studies prove mifepristone is safe and effective , and this evidence should be respected. It states that law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed, evidence-based science. The resolution affirms that the Food and Drug Administration (FDA) has the authority to regulate prescription drugs based on scientific determinations of safety and efficacy, free from political interference. The resolution highlights that the FDA has conducted multiple scientific reviews of mifepristone over 25 years, consistently finding it safe and effective for pregnancy termination, including when prescribed via telemedicine and dispensed by mail or pharmacy. It emphasizes the importance of preserving and expanding access to medication abortion care , including the ability to prescribe mifepristone through telemedicine and dispense it to eligible patients by mail or at a pharmacy. This is deemed crucial for ensuring equitable access for patients disproportionately harmed by statutory, regulatory, financial, and circumstantial restrictions, including Black and Indigenous people, people of color, immigrants, and those in rural communities.